STAB1 and neoplasm: Recently, the results from a phase I/II clinical trial show that STAB-1 blockade through the monoclonal antibody bexmarilimab leads to TAM reprogramming towards a pro-inflammatory phenotype, immune activation and tumor control in patients with late-stage cancer (56).